

25.06.2021

11:30 - 12:30 **Type: Industry satellite** **Channel 1**
Title: Industry satellite symposium - GSK

11:30 - 12:30 **TBC**

12:45 - 13:20 **Type: Opening and closure session** **Channel 1**
Title: Welcome to ESMO Gynae 2021 and Keynote address
Moderation: Susana Banerjee, GB; Domenica Lorusso, IT; Andres Maria Poveda Velasco, ES

12:45 - 12:50 **Live welcome**
A.M. Poveda Velasco, Valencia/ES

12:50 - 12:55 **Introduction to the Keynote lecture**
S. Banerjee, London/GB

12:55 - 13:20 **Keynote lecture: DNA damage repair in ovarian cancer and PARP inhibitors resistance**
A. Oza, Toronto/CA

13:35 - 14:50 **Type: Educational session** **Channel**
Title: Treatment of newly diagnosed ovarian cancer: Where are we in **1**
2021 and what's next?
Moderation: Nicole Concin, AT; David SP Tan, SG

13:35 - 13:50 **The evolving role of molecular profiling for therapeutic stratification in newly diagnosed ovarian cancer**
D.S. Tan, Singapore/SG

13:50 - 14:05 **The role of surgery for newly diagnosed ovarian cancer: Current status and future directions**
S. Mahner, Munich/DE

14:05 - 14:20 **First line maintenance therapy for ovarian cancer in 2021: What are the options?**
I. Ray-Coquard, Lyon/FR

14:20 - 14:35 **Horizon scanning: What's next for systemic therapy in ovarian cancer - first line and beyond?**
D. Lorusso, Rome/IT

14:35 - 14:50 **Live Q&A and discussion**

15:05 - 16:20 **Type: Clinical case session** **Channel**
Title: 1st line maintenance strategy options for advanced ovarian **1**
cancer by HRD profile
Moderation: David Cibula, CZ; Amit Oza, CA

15:05 - 15:25 **Clinical case - What options for HRD patients? Criteria for treatment choice**
E. Kohn, Bethesda/US

15:25 - 15:45 **Clinical case - What options for HR proficient patients? Criteria for treatment choice**
N. Colombo, Milan/IT

15:45 - 16:05 **Clinical case - Combination vs sequence: Clinical implications**
S. Lheureux, Toronto/CA

16:05 - 16:20 **Live Q&A and discussion**

16:35 - 17:35 **Type: Industry satellite** **Channel 1**
Title: Industry satellite symposium - AstraZeneca

16:35 - 17:35 **TBC**

17:50 - 19:05 **Type: YO session** **Channel 1**
Title: How to deal with the different challenges in your professional career

Moderation: Maria Kfoury, FR; Elene Mariamidze, GE; Alexandra Tyulyandina, RU

17:50 - 18:00 **How to deal with social media self-representation and networking**
D. Dizon, Providence/US

18:00 - 18:10 **How to start an international collaboration - Developing and integrating research in clinical practice**
M. Mirza, Copenhagen/DK

18:10 - 18:20 **How to seize opportunities and progress your career in the gynae-oncology field**
C. Sessa, Bellinzona/CH

18:20 - 19:05 **Live Q&A and discussion**

26.06.2021

11:30 - 12:30 **Type: Industry satellite** **Channel 1**
Title: Industry satellite symposium 3 (TBC)

11:30 - 12:30 **TBC**

12:45 - 14:15 **Type: Abstract session** **Channel 1**
Title: Best of abstracts session

Moderation: Elise Kohn, US; Domenica Lorusso, IT

12:45 - 12:55 **Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation**

A.M. Poveda Velasco, Valencia/ES

12:55 - 13:05 **Long term safety and secondary efficacy end points in the ENGOT-OV16/NOVA phase 3 trial on Niraparib in recurrent ovarian cancer**

M. Mirza, Copenhagen/DK

13:05 - 13:15 **Discussion**

E. Kohn, Bethesda/US

13:15 - 13:30 **Live Q&A and discussion**

13:30 - 13:40 **Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase 3 study**

R. Kristeleit, London/GB

13:40 - 13:50 **Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)**

K. Moore, Oklahoma City/US

13:50 - 14:00 **Discussion**

S. Banerjee, London/GB

14:00 - 14:15 **Live Q&A and discussion**

14:30 - 15:45	Type: Educational session Title: Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what's next? Moderation: Andres Maria Poveda Velasco, ES; Ignacio Romero, ES	Channel 1
14:30 - 14:50	Surgery in recurrent ovarian cancer: Patient selection and impact on 2nd line therapeutic strategies <u>P. Harter</u> , Essen/DE	
14:50 - 15:10	Do all patients with recurrent ovarian cancer need systemic therapy and which is the optimal treatment algorithm? <u>M. Friedlander</u> , Randwick/AU	
15:10 - 15:30	Current and emerging biomarkers in recurrent OvCa <u>S. Banerjee</u> , London/GB	
15:30 - 15:45	Live Q&A and discussion	
16:00 - 17:00	Type: Controversy session Title: Immunotherapy in ovarian cancer: Is there a future in clinical practice? Moderation: Robert Coleman, US; Mansoor Mirza, DK	Channel 1
16:00 - 16:15	Live introduction and first vote <u>S. Not Yet Confirmed</u> , /CH	
16:15 - 16:30	Yes <u>E. Pujade-Lauraine</u> , Paris/FR	
16:30 - 16:45	No <u>K. Moore</u> , Oklahoma City/US	
16:45 - 17:00	Second vote and live conclusions <u>S. Not Yet Confirmed</u> , /CH	
17:15 - 17:20	Type: Opening and closure session Title: Live closing remarks Moderation: Susana Banerjee, GB; Domenica Lorusso, IT; Andres Maria Poveda Velasco, ES	Channel 1
17:15 - 17:20	Live closing remarks <u>S. Not Yet Confirmed</u> , /CH	